Latest Breaking News On - Mutsuo kanzawa - Page 1 : comparemela.com

Kissei Pharmaceutical : Introduces Natural Language Processing System -November 17, 2023 at 12:10 am EST

Kissei Pharmaceutical Co., Ltd. has introduced SciBite Search, a natural language processing 1 system from SciBite Ltd. . This system is an information retrieval.

United kingdomY julien debeauvaisMutsuo kanzawaJulien debeauvaisScibite ltdKissei pharmaceutical co ltdHead officeScibite searchVice president

Correction: Kissei introduces Iktos AI Drug Discovery System

Correction: Kissei introduces Iktos AI Drug Discovery System
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

France generalMutsuo kanzawaPierre louis germainNicolas danielsYann gastonIktos softwareMono pharmaceuticalsKissei pharmaceutical co ltdChiesi groupService platformArtificial intelligenceYann gaston mathLouis germain

Correction: Kissei introduces Iktos AI Drug Discovery

Correction: Kissei introduces Iktos AI Drug Discovery
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.

France generalYann gastonPierre louis germainMutsuo kanzawaNicolas danielsIktos softwareMono pharmaceuticalsChiesi groupKissei pharmaceutical co ltdService platformArtificial intelligenceYann gaston mathLouis germain

Correction: Kissei introduces Iktos AI Drug Discovery System

Correction: Kissei introduces Iktos AI Drug Discovery System
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

France generalYann gastonPierre louis germainNicolas danielsMutsuo kanzawaChiesi groupService platformMono pharmaceuticalsKissei pharmaceutical co ltdIktos softwareArtificial intelligenceYann gaston mathLouis germain

Fostamatinib Meets Primary Endpoint in Phase 3 Trial in Japan for Treatment of Chronic Immune Thrombocytopenia

/PRNewswire/ Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that its collaboration partner, Kissei Pharmaceutical Co., Ltd. ("Kissei"), has.

United statesUnited kingdomSouth koreaCity ofRepublic of koreaWolfgang dummerEmily correiaRaul rodriguezJodi sieversDaiichi sankyoMutsuo kanzawaEli lillyRigel pharmaceuticals incExchange commissionSyneos healthImperial college london